Our strategy

• To bring unique and needed products, which we believe are undervalued, to the market
• This is done via the identification and acquisition of late-stage or marketed products with intellectual property (IP)
• The regulatory process leverages medical device status, where possible, in order to achieve a cost effective yet rapid route to market
• Once registered, Sinclair exploits its own sales and marketing operations in parallel with its extensive network of marketing partners to rapidly bring the products to market
• We utilise and combine the acquired technologies and IP to create new product concepts, adding to the product pipeline

 

Sinclair acquires, registers and commercialises undervalued products.

We focus on the niche therapeutic areas of oral health and dermatology.

We extract full value from each of our brands by a combination of sales through our own sales operations and marketing partners.

Our current portfolio includes 26 registered products in the EU and 10 in the US.